Thermo Fisher opens Swiss biologics manufacturing plant

In May last year, lab equipment giant Thermo Fisher Scientific entered a strategic partnership with CSL. Now, as part of the collaboration, Thermo Fisher has assumed operational responsibility for the biologics manufacturing site in Lengnau, Switzerland.

The Lengnau site is a 140,000 sqare meter facility that will leverage highly flexible bioproduction technologies, including both single-use and stainless steel with up to 12,500 liter bioreactor capacity.
"We are thrilled to welcome more than 200 new colleagues to Thermo Fisher," said Michel Lagarde, executive vice president of Thermo Fisher Scientific. "Through our partnership with CSL, this site further strengthens our unique customer value proposition to leverage our scale and depth of capabilities for pharma and biotech customers. With the addition of new high-volume stainless-steel capabilities in Lengnau, we are enabling our customers to start their projects with us and stay with us as their manufacturing requirements grow."

Following completion of site construction in 2022, Thermo Fisher will initially support manufacturing of CSL's next-generation recombinant factor IX product Idelvion for patients with hemophilia B. Over time, Thermo Fisher plans to expand the use of the site to include additional biopharma customers.